Table 1 Sample description
n = 208 | |
|---|---|
Characteristics | |
Females, n (%) | 136 (65.4%) |
Age, median (IQR) | 64 (60–69) |
ApoE ε4 carrier, n (%) | 63 (30.3%) |
MMSE (0–30), median (IQR) | 29 (28–30) |
CSF biomarkers | |
Aβ40, mean (SD), pg/ml | 10,850.7 (3191.4) |
Aβ42, median (IQR), pg/ml | 819.5 (577–1037) |
Ratio Aβ42/40, median (IQR) | 0.084 (0.065–0.093) |
T-tau, mean (SD), pg/ml | 318 (242–400) |
P-tau181, median (IQR), pg/ml | 37.5 (30.4–54.3) |
Ratio p-tau181/Aβ42, median (IQR) | 0.042 (0.034–0.061) |
Plasma biomarkers | |
Aβ40, median (IQR), pg/ml | 292.8 (266–318) |
Aβ42, median (IQR), pg/ml | 23.6 (21.5–26.3) |
Ratio Aβ42/40, median (IQR) | 0.082 (0.074–0.089) |
P-tau181, median (IQR), pg/ml | 1.1 (0.92–1.36) |
Ratio p-tau181/Aβ42, median (IQR) | 0.046 (0.038–0.061) |
ATN group, n (%) | |
A − T − N − | 135 (64.9%) |
A + T − N − | 50 (24%) |
A − T + N − | 1 (0.5%) |
A + T + Nx | 22 (10.6%) |